|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0017262,
umls-concept:C0017337,
umls-concept:C0026896,
umls-concept:C0030705,
umls-concept:C0039194,
umls-concept:C0111208,
umls-concept:C0185117,
umls-concept:C0205161,
umls-concept:C1280500,
umls-concept:C1519249,
umls-concept:C2911684
|
|
pubmed:issue |
1-2
|
|
pubmed:dateCreated |
2002-9-12
|
|
pubmed:abstractText |
Cytolytic T lymphocyte-associated antigen-4 (CTLA-4) plays a critical role in the down-regulation of antigen-activated immune responses. The aberrant CTLA-4 expression is characterized by low surface and intracellular levels of CTLA-4 protein, impaired up-regulation of CTLA-4 in T cells in response to ConA stimulation and high levels of soluble CTLA-4 (sCTLA-4) in serum. The serum levels of sCTLA-4 are positively correlated with the serum concentration of antibodies against the acetylcholine receptor. The (AT)(n) polymorphism in the 3'-untranslated region contributes to decreased mRNA stability and, hence, to reduced expression of CTLA-4.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD28,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD3,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Differentiation,
http://linkedlifedata.com/resource/pubmed/chemical/CTLA-4 Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/CTLA4 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Concanavalin A,
http://linkedlifedata.com/resource/pubmed/chemical/DNA,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-DR Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoconjugates,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Nicotinic,
http://linkedlifedata.com/resource/pubmed/chemical/abatacept
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0165-5728
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
130
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
224-32
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:12225905-AT Rich Sequence,
pubmed-meshheading:12225905-Adult,
pubmed-meshheading:12225905-Alleles,
pubmed-meshheading:12225905-Antigens, CD,
pubmed-meshheading:12225905-Antigens, CD28,
pubmed-meshheading:12225905-Antigens, CD3,
pubmed-meshheading:12225905-Antigens, Differentiation,
pubmed-meshheading:12225905-CTLA-4 Antigen,
pubmed-meshheading:12225905-Cells, Cultured,
pubmed-meshheading:12225905-Concanavalin A,
pubmed-meshheading:12225905-DNA,
pubmed-meshheading:12225905-Female,
pubmed-meshheading:12225905-Gene Expression Regulation,
pubmed-meshheading:12225905-HLA-DR Antigens,
pubmed-meshheading:12225905-Humans,
pubmed-meshheading:12225905-Immunoconjugates,
pubmed-meshheading:12225905-Immunosuppressive Agents,
pubmed-meshheading:12225905-Male,
pubmed-meshheading:12225905-Middle Aged,
pubmed-meshheading:12225905-Myasthenia Gravis,
pubmed-meshheading:12225905-Polymorphism, Genetic,
pubmed-meshheading:12225905-RNA, Messenger,
pubmed-meshheading:12225905-Receptors, Nicotinic,
pubmed-meshheading:12225905-T-Lymphocytes,
pubmed-meshheading:12225905-Up-Regulation
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequence.
|
|
pubmed:affiliation |
Immunological Research Unit, Department of Medicine, Center for Molecular Medicine (CMM) L8: 03, Karolinska Institutet, Karolinska Hospital, S-17176, Stockholm, Sweden.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
